[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CU20070094A7 - Formas de dosificación oral sólidas que contienen una dosis baja de estradiol - Google Patents

Formas de dosificación oral sólidas que contienen una dosis baja de estradiol

Info

Publication number
CU20070094A7
CU20070094A7 CU20070094A CU20070094A CU20070094A7 CU 20070094 A7 CU20070094 A7 CU 20070094A7 CU 20070094 A CU20070094 A CU 20070094A CU 20070094 A CU20070094 A CU 20070094A CU 20070094 A7 CU20070094 A7 CU 20070094A7
Authority
CU
Cuba
Prior art keywords
dosage forms
estradiol
solid oral
oral dosage
forms containing
Prior art date
Application number
CU20070094A
Other languages
English (en)
Inventor
Christian Zurth
Kristina Mueller
Torsten Wagner
Adrian Funke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20070094A7 publication Critical patent/CU20070094A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a formas de dosificación oral sólidas que contienen una dosis muy baja de estradiol. Las formas de dosificación se formulan de modotal que se evita la degradación del estradiol y se minimiza el contenido de polivinilpirrolidona, al tiempo que aún se logra una disolución rápida similar a la del estradiol. Las formas de dosificación son útiles para prevenir o tratar una condición física provocada en una mujer por niveles endógenos insuficientes de estradiol.
CU20070094A 2004-11-02 2007-04-30 Formas de dosificación oral sólidas que contienen una dosis baja de estradiol CU20070094A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02

Publications (1)

Publication Number Publication Date
CU20070094A7 true CU20070094A7 (es) 2009-09-08

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070094A CU20070094A7 (es) 2004-11-02 2007-04-30 Formas de dosificación oral sólidas que contienen una dosis baja de estradiol

Country Status (21)

Country Link
EP (1) EP1814526A2 (es)
JP (1) JP2008518895A (es)
KR (1) KR20070085558A (es)
CN (1) CN101094656A (es)
AR (1) AR053650A1 (es)
AU (1) AU2005300658A1 (es)
BR (1) BRPI0517940A (es)
CA (1) CA2585095A1 (es)
CR (1) CR9112A (es)
CU (1) CU20070094A7 (es)
EA (1) EA013262B1 (es)
GT (1) GT200500315A (es)
IL (1) IL182635A0 (es)
MX (1) MX2007005281A (es)
NO (1) NO20072704L (es)
PA (1) PA8651401A1 (es)
PE (1) PE20061126A1 (es)
TW (1) TW200621312A (es)
UY (1) UY29185A1 (es)
WO (1) WO2006048261A2 (es)
ZA (1) ZA200705012B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
WO2011128337A2 (en) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Low-dosed solid oral dosage forms for hrt
EA026095B1 (ru) 2010-04-15 2017-03-31 Байер Интеллекчуал Проперти Гмбх Очень низкодозированные твердые пероральные лекарственные формы для гормонозаместительной терапии (гзт)
CN112516149B (zh) * 2020-07-21 2023-07-18 南方医科大学 苯甲酸雌二醇或其药物可接受盐在制备抗冠状病毒的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (es) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
ATE532521T1 (de) * 2000-12-15 2011-11-15 Novo Nordisk Femcare Ag Verwendung eines östrogens bei der herstellung einer östrogenhaltigen zusammensetzung zur behandlung von atrophischer vaginitis
FR2823976A1 (fr) * 2001-04-25 2002-10-31 Theramex Nouvelle composition hormonale et son utilisation
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (ja) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 更年期症の予防・治療用経口組成物

Also Published As

Publication number Publication date
AU2005300658A1 (en) 2006-05-11
UY29185A1 (es) 2006-05-31
AR053650A1 (es) 2007-05-16
TW200621312A (en) 2006-07-01
EP1814526A2 (en) 2007-08-08
JP2008518895A (ja) 2008-06-05
EA200700979A1 (ru) 2007-10-26
EA013262B1 (ru) 2010-04-30
BRPI0517940A (pt) 2008-10-21
CR9112A (es) 2007-11-23
CA2585095A1 (en) 2006-05-11
NO20072704L (no) 2007-05-29
GT200500315A (es) 2006-06-06
CN101094656A (zh) 2007-12-26
MX2007005281A (es) 2008-03-11
WO2006048261A2 (en) 2006-05-11
KR20070085558A (ko) 2007-08-27
IL182635A0 (en) 2007-07-24
ZA200705012B (en) 2008-10-29
PA8651401A1 (es) 2006-12-07
WO2006048261A3 (en) 2006-09-21
PE20061126A1 (es) 2006-11-11

Similar Documents

Publication Publication Date Title
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR050418A1 (es) Dosificacion fija de anticuerpos her
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
CU20070094A7 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
AR109263A2 (es) Composición que comprende moxidectina
BRPI0414428A (pt) composições farmacêuticas
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
ES2421731T3 (es) Composición y procedimiento para el tratamiento de MRSA
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR050572A1 (es) Composiciones germicidas que contienen mezclas de ftalaldehidos y metodos de uso de dichas composiciones para desinfeccion o esterilizacion
AR080541A1 (es) Tratamiento para la endometriosis
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral